BioMarin Pharmaceutical Inc.

BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia

12 Dec 2016 08:29:22 By Nasdaq GlobeNewswire

BioMarin to Attend Three Upcoming Investor Conferences

03 Nov 2016 08:30:46 By Nasdaq GlobeNewswire

BioMarin Announces Third Quarter 2016 Financial Results

27 Oct 2016 16:03:46 By Nasdaq GlobeNewswire

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting

19 Oct 2016 17:01:21 By Nasdaq GlobeNewswire

UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A

13 Oct 2016 16:01:29 By Nasdaq GlobeNewswire

BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET

11 Oct 2016 08:31:09 By Nasdaq GlobeNewswire

BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics

21 Sep 2016 08:54:15 By Nasdaq GlobeNewswire

BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease

15 Sep 2016 08:38:09 By Nasdaq GlobeNewswire

BioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting

08 Sep 2016 04:30:29 By Nasdaq GlobeNewswire

BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease

06 Sep 2016 16:06:27 By Nasdaq GlobeNewswire

BioMarin to Attend Upcoming Investor Conferences

31 Aug 2016 08:30:53 By Nasdaq GlobeNewswire

Forbes Ranks BioMarin 10th Most Innovative Company in the World

24 Aug 2016 09:54:01 By Nasdaq GlobeNewswire

BioMarin Announces Pricing of Public Offering of Common Stock

09 Aug 2016 09:01:46 By Nasdaq GlobeNewswire

BioMarin Announces Public Offering of Common Stock

08 Aug 2016 16:33:15 By Nasdaq GlobeNewswire

BioMarin Announces Second Quarter 2016 Financial Results

04 Aug 2016 16:03:46 By Nasdaq GlobeNewswire

FDA Accepts BLA for BioMarin’s Cerliponase Alfa for CLN2 Disease, Form of Batten Disease

27 Jul 2016 18:02:06 By Nasdaq GlobeNewswire

BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress

27 Jul 2016 14:30:15 By Nasdaq GlobeNewswire

BioMarin to Provide Updated Data for BMN 270 in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress July 27th

21 Jul 2016 16:03:31 By Nasdaq GlobeNewswire